文献速递外周动脉疾病

Absorb依维莫司洗脱生物可吸收血管支架在膝下动脉的三年结果

Three-Year Results of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Infrapopliteal Arteries.
PubMed 文献 · J Endovasc Ther · 2018-09-12

单中心前瞻性研究纳入48例有症状患者(平均年龄82.1±8.0岁,27例男性),于2013年9月至2018年2月在远端腘动脉和胫动脉病变中评估Absorb依维莫司洗脱生物可吸收血管支架。平均病变长度20.1±10.8 mm,55条肢体植入支架。随访显示12、24、36个月主要通畅率分别为92.2%、90.3%、81.1%,免于临床驱动的靶病变血运重建率分别为97.2%、97.2%、87.3%,无晚期支架血栓形成。

要点

  • 技术成功率达100%,30天内无截肢、死亡或靶肢体旁路手术。
  • 12、24、36个月主要通畅率分别为92.2%、90.3%、81.1%。
  • 55条肢体中93%临床改善,39条组织缺损肢体中92%完全愈合,无重大截肢。

核心结论

  • 中期随访显示Absorb生物可吸收血管支架在膝下动脉具有优异的安全性、通畅率和免于临床驱动的靶病变血运重建率。

研究设计与样本

  • 单中心前瞻性研究,2013年9月至2018年2月纳入48例有症状患者(平均年龄82.1±8.0岁;27例男性),评估远端腘动脉和胫动脉病变,平均病变长度20.1±10.8 mm,55条肢体预扩张后植入最多2个Absorb依维莫司洗脱生物可吸收血管支架。

主要发现

  • 共植入71个支架治疗61处病变;技术成功所有患者均达成,30天内无截肢、死亡或靶肢体旁路手术。
  • 1例既往抗凝且术后未给抗血小板药物的患者发生2个支架的早期血栓性闭塞。
  • 平均随访24.0±15.3个月期间,11例(23%)患者死亡,剩余37例可随访。
  • 6个(8%)支架检出二元再狭窄(50%-75%);12、24、36个月主要通畅率分别为92.2%、90.3%、81.1%,免于临床驱动的靶病变血运重建率分别为97.2%、97.2%、87.3%。
  • 未观察到晚期支架血栓形成;55条肢体中51条(93%)临床改善,4条(7%)无变化;39条因组织缺损治疗的肢体中36条(92%)完全伤口愈合,无重大截肢(肢体挽救率100%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the midterm performance of the everolimus-eluting Absorb bioresorbable vascular scaffold (BVS) for the treatment of symptomatic infrapopliteal atherosclerotic disease. METHODS: A single-center study prospectively enrolled 48 symptomatic patients (mean age 82.1±8.0 years; 27 men) between September 2013 and February 2018 to evaluate the Absorb everolimus-eluting BVS system in distal popliteal and tibial lesions. Mean lesion length was 20.1±10.8 mm. Following predilation, up to 2 BVS were implanted in target lesions in 55 limbs. Clinical and duplex ultrasound follow-up was performed at 1, 3, 6, 12, 24, 36, and 48 months to determine 30-day morbidity and midterm Kaplan-Meier estimates of binary restenosis, clinically-driven target lesion revascularization (CD-TLR), amputation, and mortality. RESULTS: Seventy-one scaffolds were implanted to treat 61 lesions. Technical success was achieved in all patients, with no amputation, death, or target limb bypass surgery within 30 days of the index procedure. There was 1 early thrombotic occlusion of 2 BVS in a previously anticoagulated patient not given antiplatelet medication after the procedure. During a mean follow-up of 24.0±15.3 months, 11 (23%) patients died; the remaining 37 were available for follow-up. Binary restenosis (50%-75%) was detected in 6 (8%) scaffolds. Primary patency estimates at 12, 24, and 36 months were 92.2%, 90.3%, and 81.1%; freedom from CD-TLR estimates were 97.2%, 97.2%, and 87.3% at the same time points. No late scaffold thrombosis has been observed. The majority of the 55 limbs (51, 93%) were clinically improved; 4 (7%) were unchanged. Thirty-six (92%) of 39 limbs treated for tissue loss achieved complete wound healing, with no major amputation (limb salvage 100%). CONCLUSION: Midterm follow-up demonstrates excellent safety, patency, and freedom from CD-TLR rates using the Absorb bioresorbable vascular scaffold below the knee.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Varcoe RL, Thomas SD, Lennox AF, et al. Three-Year Results of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Infrapopliteal Arteries. J Endovasc Ther. 2018. PMID: 30205736. doi:10.1177/1526602818799736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。